Metabolic Syndrome: Underlying Mechanisms and Drug Therapies covers the development of metabolic syndrome, the underlying mechanisms and therapeutic strategies for drug development.

The book examines the context of underlying molecular pathways and integrated physiology, then expanding the discussion to diseases associated with metabolic syndrome.

The development of drug therapies for these diseases and complications is extensively covered. The book also offers a comprehensive and in-depth view of energy metabolism, metabolic tissues and pathways, molecular mechanism-based drug discovery and clinical implications.

Features:

• Addresses important metabolic syndrome basics at the psychological level and metabolic abnormalities at the tissue and pathway levels
• Covers the identification of pathways and molecular targets for the development of anti-diabetic therapies
• Details pharmaceutical industry approach to solving matabolic and obesity related problems
• Describes drug therapies and their limitations and complications, offering a "lessons learned" from existing treatments

Contents

Part I. The physiology of metabolic tissues under normal and disease states

1. Gut as an endocrine organ: the role of nutrient-sensing in energy metabolism
2. Central glucose sensing and control of food intake and energy homeostasis
3. Abnormalities in insulin secretion in type 2 diabetes mellitus
4. Adipokine production by adipose tissue: A novel target for treating metabolic syndrome and its sequelae
5. Hepatic metabolic dysfunctions in type 2 diabetes: Insulin resistance and impaired glucose production and lipid synthesis
6. Energy metabolism in skeletal muscle and its link to insulin resistance

Part II. Metabolic diseases and current therapies

7. Mechanisms and complications of metabolic syndrome
8. Emerging therapeutic approaches for dyslipidemia associated with high LDL and low HDL
9. Mechanism of action of niacin: implications for atherosclerosis and drug discovery
10. Current anti-diabetic therapies and mechanisms

Part III. Drug targets for anti-diabetic therapies

11. GLP-1 biology, signaling mechanisms, physiology, and clinical studies
12. Dipeptidyl peptidase IV inhibitors for treatment of diabetes
13. Sodium glucose co-transporter 2 inhibitors
14. Fibroblast growth factor 21 as a novel metabolic regulator
15. Sirtuins as potential drug targets for metabolic diseases
16. 11?-hydroxysteroid dehydrogenase type 1 as a therapeutic target for type 2 diabetes
17. Monoclonal antibodies for the treatment of type 2 diabetes: A case study with glucagon receptor blockade

Part IV. Lessons learned and future outlook

18. Drug development for metabolic diseases: past, present and future

Index

click here to see books of related interest